Loading cancer entity…
Loading cancer entity…
Clinical trials
1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03226119 | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study | completed | Phase 4 | 150 | MP Biomedicals, LLCINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00221039 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | completed | Phase 4 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01569724 | Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma(TgBEX) | completed | Phase 4 | 10 | Rennes University HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01664975 | Treatment of Peripheral T-cell Lymphoma | completed | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01418430 | Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) | completed | Phase 4 | — | King's College Hospital NHS TrustOTHER | 1 | Aug 22, 2011 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | completed | Phase 4 | 86 | Eisai Inc.INDUSTRY | 9 | Mar 5, 2008 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials